Vol. 19/No.5 | OncologyLive

How Durable Are CAR T-Cell Therapies?

March 01, 2018

The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.

Is the Median All We Should Offer Our Patients?

February 28, 2018

Although median survival is a reasonable endpoint to highlight, it is only 1 of many relevant outcome factors to discuss, and, most important, this mathematical figure simply does not define the survival of any particular patient.